Stocktoria
SERA PROGNOSTICS, INC. SERA
SERA PROGNOSTICS, INC. (SERA) earns a Piotroski F-score of 2/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $81,000 at a -39417.3% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Services · percentile among 982 companies
Percentile vs other Services companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.163 |
| Retained earnings / assets | -3.058 |
| EBIT / assets | -0.358 |
| Equity / liabilities | 2.843 |
Sector peers · similar-size Services companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| SERA | SERA PROGNOSTICS, INC. | 2/9 | -8.32 | — | — |
| ACON | Aclarion, Inc. | 4/9 | 4.23 | — | — |
| YDES | YD Bio Ltd | 1/9 | -1.35 | — | — |
| BGLC | BioNexus Gene Lab Corp | 4/9 | 13.26 | — | — |
| CFOR | CapForce Inc. | 2/9 | -14.09 | 1 | — |
| XGN | EXAGEN INC. | 3/9 | -14.91 | — | +19.7% |
| PSNL | Personalis, Inc. | 3/9 | 0.31 | — | -17.7% |
About SERA PROGNOSTICS, INC.
Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation. It is also involved in the development of a pipeline of novel blood-based biomarker tests and predictive analytic products and services for pregnancy related conditions, such as time-to-birth, predictive analytics product, pregnancy risk prediction panel, preeclampsia, and fetal growth restriction. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
FAQ
Is SERA financially healthy?
SERA PROGNOSTICS, INC.'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does SERA pay a dividend?
No, SERA PROGNOSTICS, INC. does not currently pay a dividend.
How profitable is SERA?
In FY2025, SERA PROGNOSTICS, INC. had a net margin of -39417.3% and a return on equity of -42.3%.
What is the analyst price target for SERA?
The average Wall-Street price target for SERA PROGNOSTICS, INC. is $5.50, about 172.3% above the recent price, from 2 analysts.
Is SERA a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on SERA PROGNOSTICS, INC.: a Piotroski F-score of 2/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.